A Phase I, Double-Blind, Double-Dummy, Placebo-Controlled, Randomised, Four-Period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (10mg and 30mg) on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Volunteers Aged 18 to 45 Years

Trial Profile

A Phase I, Double-Blind, Double-Dummy, Placebo-Controlled, Randomised, Four-Period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (10mg and 30mg) on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Volunteers Aged 18 to 45 Years

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2010

At a glance

  • Drugs Moxifloxacin; Zibotentan
  • Indications Bacterial infections; Non-small cell lung cancer; Ovarian cancer; Prostate cancer
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 05 Oct 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 02 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top